2025 H2 -tulosraportti
175 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 min sittenBiotech is now mega hot. Let's get SS Thor up 125 % then..in 1 day... FOMO in US now. Does it spill over to OSE..?? They make it happen on Nasdaq ⛵ See picture.
·2 t sittenReferring to my last post which I published before Thor reported that the factory is working. My estimate was 6-8 kr per share, which has proven quite accurate. I know this stock, and have been invested ever since they were called Nano. Now we are waiting for Thor to report that some Big Pharma has a medicine that needs Thorium. That could happen soon. Then the stock will jump tremendously, provided that Thor can increase capacity swiftly. Then we will see 20-30 kroner. In the long term, this can go very high.
Capacity is probably a keyword here. Can it be scaled easily or does it require a new/expanded factory and will be both costly and time-consuming?
·3 t sittenBright prospects for ThorMed. https://www.nettavisen.no/okonomi/thor-medical-skyter-fart-pa-oslo-bors/s/80-95-4118
In Norway, the corporate tax is 22 %. With approx. 3.06 billion kroner in tax loss carryforwards, this provides a theoretical tax benefit of: 3 060 000 000 × 0.22 = approx. 673 million kroner This means that Thor Medical can practically earn around 3 billion in taxable profit before they start paying corporate tax. The losses can be carried forward indefinitely.- ·4 t sittenThe skipper here. I easily crushed the slow sailor who was slow to get the mainsail up today. The last thing he said was that SS Thor is sailing north and will go to a new top increase to kr 8.30 or MORE.👌 There's a bit of resistance there. He said he had read an analysis on Investtech....🇧🇻💰 Technical analysis. Medium term, 20. Aug 2026 Thor Medical ASA is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development and that buying interest among investors is increasing. The stock also gave a buy signal from a rectangle formation upon breaking through the resistance at 5.98 kroner. Further upside to 8.30 kroner or more is signaled. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 5.50 kroner. Volume has previously been high around price tops and low around price bottoms. This strengthens the trend picture. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price appreciation for Thor Medical ASA.
·5 t sittenhttps://www.dn.no/bors/bioteknologi/moderna/nykode-therapeutics/strong-rebound-for-bombed-out-sector-absolutely-extreme/2-1-2031606
Strong rebound for "bombed out" sector: – Absolutely extreme DNB fund manager Benedicte Bakke still sees opportunities in biotech, but her funds own no Norwegian companies. ABG analyst believes Norwegian companies are too small for many investors. – We still see several companies with attractive valuations. Even though the sector has moved a lot, we think there is more to gain, because the fundamental conditions are very good, says DNB fund manager Benedicte Bakke. Several biotech stocks have had a strong upturn after several weak years, and the Nasdaq Biotechnology Index is up nearly 60 percent in the last year. On Wednesday, the sector gained new momentum after positive Phase 3 results from Moderna. On the Oslo Stock Exchange, Nykode Therapeutics rose over 50 percent. Bakke believes the market is pricing in that Moderna's technology can also succeed against other forms of cancer. Currently, there is only data on melanoma. – A lot of the success in melanoma was priced in already before yesterday, and then they had a significant price development. It's absolutely extreme, says Bakke. She also believes that a short squeeze in Moderna and significant buying activity from small investors contributed to reinforcing the price increase. ABG Sundal Collier analyst Georg Tigalonov-Bjerke states that the turnaround for the sector came early in 2025. – It has clearly performed stronger recently. It comes from low levels where it has been completely bombed out. It is often typical for the sector that when it falls, it perhaps falls too much, and when it rises, it rises too much, says Tigalonov-Bjerke. When it comes to pricing, Bakke believes that the largest companies in the Nasdaq index are largely correctly priced. In the segments below, there are several attractive opportunities. In addition, acquisitions can provide a boost. – There is a need for more acquisitions from the large pharmaceutical companies, which have patent expirations and earnings they need to fill. They often do this with acquisitions, says Bakke. As an attractive example, she mentions Argenx, which has developed from an early-stage development company into a large commercial biotech company. – It is a good example of a biotechnology company that is solid and delivers. It is an innovation machine, says Bakke. No Norwegian companies in the mix In Norway, however, she does not see equally good buying opportunities. Despite believing that Norwegian research environments maintain a high standard, she sees no companies that fit the fund's risk profile. – Norway has a lot of good research. What we unfortunately haven't succeeded with yet is creating companies that have succeeded with good clinical data. I would very much like to see more success stories in Norway, says Bakke. She particularly points to the access to risk capital as a hindering factor. – There is a lot of early stage, and Norway also struggles with a lack of risk-willing capital to build companies with multiple assets and invest more. It is a fact that we have less risk-willing capital in Norway than, for example, in the USA, says Bakke. For the DNB funds, size, clinical data, and liquidity also play a role. In the biotech fund, they typically look for companies worth more than around 500 million dollars and with so-called "proof of concept". – It is important that there is liquidity in the stock. If I want to sell the stock today, I should be able to get rid of all the shares today. In the companies on the Oslo Stock Exchange, there is also less liquidity, and that matters, says Bakke. Points to greater interest in Sweden Tigalonov-Bjerke also points to the need for liquidity. He covers 13 companies in the biotech sector, especially in Sweden, where he believes investor interest is greater. – You need a bit more liquidity and perhaps a bit more stability if you are to be an institutional investor and invest. Then some of the Norwegian ones are simply too small, says Tigalonov-Bjerke Although he emphasizes that Norway has a good professional environment, especially in the cancer field, he believes that Sweden has a broader environment among companies and investors. – Sweden has a different entrepreneurial culture when it comes to forming successful businesses, attracting and retaining talent, says Tigalonov-Bjerke. Mentions three Norwegian companies Nevertheless, there are Norwegian companies Tigalonov-Bjerke considers interesting. Among the biotech companies he follows, Nykode is the favorite. ABG has a buy recommendation on the stock, but the analyst emphasizes that it is a "high risk, high reward" case. He also mentions Oncoinvent, where he believes the risk lies more in the financing than in the technology. – I believe their technology works, but it's a long way to get it approved, because you're going to need quite a lot of money along the way, says Tigalonov-Bjerke. A third company he mentions is Thor Medical, which supplies radioactive isotopes to pharmaceutical companies and is thus less dependent on a single clinical study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
175 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenBiotech is now mega hot. Let's get SS Thor up 125 % then..in 1 day... FOMO in US now. Does it spill over to OSE..?? They make it happen on Nasdaq ⛵ See picture.
- ·2 t sittenReferring to my last post which I published before Thor reported that the factory is working. My estimate was 6-8 kr per share, which has proven quite accurate. I know this stock, and have been invested ever since they were called Nano. Now we are waiting for Thor to report that some Big Pharma has a medicine that needs Thorium. That could happen soon. Then the stock will jump tremendously, provided that Thor can increase capacity swiftly. Then we will see 20-30 kroner. In the long term, this can go very high.Capacity is probably a keyword here. Can it be scaled easily or does it require a new/expanded factory and will be both costly and time-consuming?
- ·3 t sittenBright prospects for ThorMed. https://www.nettavisen.no/okonomi/thor-medical-skyter-fart-pa-oslo-bors/s/80-95-4118In Norway, the corporate tax is 22 %. With approx. 3.06 billion kroner in tax loss carryforwards, this provides a theoretical tax benefit of: 3 060 000 000 × 0.22 = approx. 673 million kroner This means that Thor Medical can practically earn around 3 billion in taxable profit before they start paying corporate tax. The losses can be carried forward indefinitely.
- ·4 t sittenThe skipper here. I easily crushed the slow sailor who was slow to get the mainsail up today. The last thing he said was that SS Thor is sailing north and will go to a new top increase to kr 8.30 or MORE.👌 There's a bit of resistance there. He said he had read an analysis on Investtech....🇧🇻💰 Technical analysis. Medium term, 20. Aug 2026 Thor Medical ASA is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development and that buying interest among investors is increasing. The stock also gave a buy signal from a rectangle formation upon breaking through the resistance at 5.98 kroner. Further upside to 8.30 kroner or more is signaled. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 5.50 kroner. Volume has previously been high around price tops and low around price bottoms. This strengthens the trend picture. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price appreciation for Thor Medical ASA.
- ·5 t sittenhttps://www.dn.no/bors/bioteknologi/moderna/nykode-therapeutics/strong-rebound-for-bombed-out-sector-absolutely-extreme/2-1-2031606Strong rebound for "bombed out" sector: – Absolutely extreme DNB fund manager Benedicte Bakke still sees opportunities in biotech, but her funds own no Norwegian companies. ABG analyst believes Norwegian companies are too small for many investors. – We still see several companies with attractive valuations. Even though the sector has moved a lot, we think there is more to gain, because the fundamental conditions are very good, says DNB fund manager Benedicte Bakke. Several biotech stocks have had a strong upturn after several weak years, and the Nasdaq Biotechnology Index is up nearly 60 percent in the last year. On Wednesday, the sector gained new momentum after positive Phase 3 results from Moderna. On the Oslo Stock Exchange, Nykode Therapeutics rose over 50 percent. Bakke believes the market is pricing in that Moderna's technology can also succeed against other forms of cancer. Currently, there is only data on melanoma. – A lot of the success in melanoma was priced in already before yesterday, and then they had a significant price development. It's absolutely extreme, says Bakke. She also believes that a short squeeze in Moderna and significant buying activity from small investors contributed to reinforcing the price increase. ABG Sundal Collier analyst Georg Tigalonov-Bjerke states that the turnaround for the sector came early in 2025. – It has clearly performed stronger recently. It comes from low levels where it has been completely bombed out. It is often typical for the sector that when it falls, it perhaps falls too much, and when it rises, it rises too much, says Tigalonov-Bjerke. When it comes to pricing, Bakke believes that the largest companies in the Nasdaq index are largely correctly priced. In the segments below, there are several attractive opportunities. In addition, acquisitions can provide a boost. – There is a need for more acquisitions from the large pharmaceutical companies, which have patent expirations and earnings they need to fill. They often do this with acquisitions, says Bakke. As an attractive example, she mentions Argenx, which has developed from an early-stage development company into a large commercial biotech company. – It is a good example of a biotechnology company that is solid and delivers. It is an innovation machine, says Bakke. No Norwegian companies in the mix In Norway, however, she does not see equally good buying opportunities. Despite believing that Norwegian research environments maintain a high standard, she sees no companies that fit the fund's risk profile. – Norway has a lot of good research. What we unfortunately haven't succeeded with yet is creating companies that have succeeded with good clinical data. I would very much like to see more success stories in Norway, says Bakke. She particularly points to the access to risk capital as a hindering factor. – There is a lot of early stage, and Norway also struggles with a lack of risk-willing capital to build companies with multiple assets and invest more. It is a fact that we have less risk-willing capital in Norway than, for example, in the USA, says Bakke. For the DNB funds, size, clinical data, and liquidity also play a role. In the biotech fund, they typically look for companies worth more than around 500 million dollars and with so-called "proof of concept". – It is important that there is liquidity in the stock. If I want to sell the stock today, I should be able to get rid of all the shares today. In the companies on the Oslo Stock Exchange, there is also less liquidity, and that matters, says Bakke. Points to greater interest in Sweden Tigalonov-Bjerke also points to the need for liquidity. He covers 13 companies in the biotech sector, especially in Sweden, where he believes investor interest is greater. – You need a bit more liquidity and perhaps a bit more stability if you are to be an institutional investor and invest. Then some of the Norwegian ones are simply too small, says Tigalonov-Bjerke Although he emphasizes that Norway has a good professional environment, especially in the cancer field, he believes that Sweden has a broader environment among companies and investors. – Sweden has a different entrepreneurial culture when it comes to forming successful businesses, attracting and retaining talent, says Tigalonov-Bjerke. Mentions three Norwegian companies Nevertheless, there are Norwegian companies Tigalonov-Bjerke considers interesting. Among the biotech companies he follows, Nykode is the favorite. ABG has a buy recommendation on the stock, but the analyst emphasizes that it is a "high risk, high reward" case. He also mentions Oncoinvent, where he believes the risk lies more in the financing than in the technology. – I believe their technology works, but it's a long way to get it approved, because you're going to need quite a lot of money along the way, says Tigalonov-Bjerke. A third company he mentions is Thor Medical, which supplies radioactive isotopes to pharmaceutical companies and is thus less dependent on a single clinical study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
175 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenBiotech is now mega hot. Let's get SS Thor up 125 % then..in 1 day... FOMO in US now. Does it spill over to OSE..?? They make it happen on Nasdaq ⛵ See picture.
- ·2 t sittenReferring to my last post which I published before Thor reported that the factory is working. My estimate was 6-8 kr per share, which has proven quite accurate. I know this stock, and have been invested ever since they were called Nano. Now we are waiting for Thor to report that some Big Pharma has a medicine that needs Thorium. That could happen soon. Then the stock will jump tremendously, provided that Thor can increase capacity swiftly. Then we will see 20-30 kroner. In the long term, this can go very high.Capacity is probably a keyword here. Can it be scaled easily or does it require a new/expanded factory and will be both costly and time-consuming?
- ·3 t sittenBright prospects for ThorMed. https://www.nettavisen.no/okonomi/thor-medical-skyter-fart-pa-oslo-bors/s/80-95-4118In Norway, the corporate tax is 22 %. With approx. 3.06 billion kroner in tax loss carryforwards, this provides a theoretical tax benefit of: 3 060 000 000 × 0.22 = approx. 673 million kroner This means that Thor Medical can practically earn around 3 billion in taxable profit before they start paying corporate tax. The losses can be carried forward indefinitely.
- ·4 t sittenThe skipper here. I easily crushed the slow sailor who was slow to get the mainsail up today. The last thing he said was that SS Thor is sailing north and will go to a new top increase to kr 8.30 or MORE.👌 There's a bit of resistance there. He said he had read an analysis on Investtech....🇧🇻💰 Technical analysis. Medium term, 20. Aug 2026 Thor Medical ASA is in a rising trend channel in the medium term. Rising trends indicate that the company is in a positive development and that buying interest among investors is increasing. The stock also gave a buy signal from a rectangle formation upon breaking through the resistance at 5.98 kroner. Further upside to 8.30 kroner or more is signaled. There is no resistance in the price chart and further upside is indicated. In case of reactions back, the stock has support at approximately 5.50 kroner. Volume has previously been high around price tops and low around price bottoms. This strengthens the trend picture. The short-term momentum in the stock is strongly positive, with RSI over 70. This indicates increasing optimism among investors and further price appreciation for Thor Medical ASA.
- ·5 t sittenhttps://www.dn.no/bors/bioteknologi/moderna/nykode-therapeutics/strong-rebound-for-bombed-out-sector-absolutely-extreme/2-1-2031606Strong rebound for "bombed out" sector: – Absolutely extreme DNB fund manager Benedicte Bakke still sees opportunities in biotech, but her funds own no Norwegian companies. ABG analyst believes Norwegian companies are too small for many investors. – We still see several companies with attractive valuations. Even though the sector has moved a lot, we think there is more to gain, because the fundamental conditions are very good, says DNB fund manager Benedicte Bakke. Several biotech stocks have had a strong upturn after several weak years, and the Nasdaq Biotechnology Index is up nearly 60 percent in the last year. On Wednesday, the sector gained new momentum after positive Phase 3 results from Moderna. On the Oslo Stock Exchange, Nykode Therapeutics rose over 50 percent. Bakke believes the market is pricing in that Moderna's technology can also succeed against other forms of cancer. Currently, there is only data on melanoma. – A lot of the success in melanoma was priced in already before yesterday, and then they had a significant price development. It's absolutely extreme, says Bakke. She also believes that a short squeeze in Moderna and significant buying activity from small investors contributed to reinforcing the price increase. ABG Sundal Collier analyst Georg Tigalonov-Bjerke states that the turnaround for the sector came early in 2025. – It has clearly performed stronger recently. It comes from low levels where it has been completely bombed out. It is often typical for the sector that when it falls, it perhaps falls too much, and when it rises, it rises too much, says Tigalonov-Bjerke. When it comes to pricing, Bakke believes that the largest companies in the Nasdaq index are largely correctly priced. In the segments below, there are several attractive opportunities. In addition, acquisitions can provide a boost. – There is a need for more acquisitions from the large pharmaceutical companies, which have patent expirations and earnings they need to fill. They often do this with acquisitions, says Bakke. As an attractive example, she mentions Argenx, which has developed from an early-stage development company into a large commercial biotech company. – It is a good example of a biotechnology company that is solid and delivers. It is an innovation machine, says Bakke. No Norwegian companies in the mix In Norway, however, she does not see equally good buying opportunities. Despite believing that Norwegian research environments maintain a high standard, she sees no companies that fit the fund's risk profile. – Norway has a lot of good research. What we unfortunately haven't succeeded with yet is creating companies that have succeeded with good clinical data. I would very much like to see more success stories in Norway, says Bakke. She particularly points to the access to risk capital as a hindering factor. – There is a lot of early stage, and Norway also struggles with a lack of risk-willing capital to build companies with multiple assets and invest more. It is a fact that we have less risk-willing capital in Norway than, for example, in the USA, says Bakke. For the DNB funds, size, clinical data, and liquidity also play a role. In the biotech fund, they typically look for companies worth more than around 500 million dollars and with so-called "proof of concept". – It is important that there is liquidity in the stock. If I want to sell the stock today, I should be able to get rid of all the shares today. In the companies on the Oslo Stock Exchange, there is also less liquidity, and that matters, says Bakke. Points to greater interest in Sweden Tigalonov-Bjerke also points to the need for liquidity. He covers 13 companies in the biotech sector, especially in Sweden, where he believes investor interest is greater. – You need a bit more liquidity and perhaps a bit more stability if you are to be an institutional investor and invest. Then some of the Norwegian ones are simply too small, says Tigalonov-Bjerke Although he emphasizes that Norway has a good professional environment, especially in the cancer field, he believes that Sweden has a broader environment among companies and investors. – Sweden has a different entrepreneurial culture when it comes to forming successful businesses, attracting and retaining talent, says Tigalonov-Bjerke. Mentions three Norwegian companies Nevertheless, there are Norwegian companies Tigalonov-Bjerke considers interesting. Among the biotech companies he follows, Nykode is the favorite. ABG has a buy recommendation on the stock, but the analyst emphasizes that it is a "high risk, high reward" case. He also mentions Oncoinvent, where he believes the risk lies more in the financing than in the technology. – I believe their technology works, but it's a long way to get it approved, because you're going to need quite a lot of money along the way, says Tigalonov-Bjerke. A third company he mentions is Thor Medical, which supplies radioactive isotopes to pharmaceutical companies and is thus less dependent on a single clinical study.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt